Figure 3

EGFR L861Q amplification curve for each specimen by the peptide nucleic acid-locked nucleic acid PCR clamp test. A) Small-cell lung cancer component of the specimen at the time of initial diagnosis. B) Adenocarcinoma component of the specimen at the time of initial diagnosis. C) Adenocarcinoma at the time of disease progression after cisplatin-irinotecan therapy. D) Small-cell lung cancer at the time of disease progression after erlotinib therapy.